Clear Filters
13 results
Page of 2
  • A011202

    A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • A011401 / BWel Trial

    Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • A011502 / ABC Trial

    A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

    For inquiries at Newark Beth Israel Medical Center, call (973) 926-7230

    For inquiries at Monmouth Medical Center, call (732) 923-6564

    For inquiries at RWJ Somerset Medical Center, call (908) 685-2481

    For inquiries at Community Medical Center, call (732) 557-8294

    • Monmouth Medical Center
    • Community Medical Center
    • Newark Beth Israel Medical Center
    • RWJ University Hospital Somerset
  • A081105

    Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • A151216 ALCHEMIST

    Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

    For inquiries at RWJ University Hospital Somerset, call (908) 685-2481

    For inquiries at Monmouth Medical Center, call (732) 923-6564

    • Monmouth Medical Center
    • RWJ University Hospital Somerset
  • Connect MDS-AML - Connect® MDS/AML Disease Registry

    The purpose of the Connect® MDS/AML Disease Registry is to provide unique insights into treatment regimens and sequencing of these regimens as they relate to clinical outcomes of patients with newly diagnosed MDS, ICUS or AML in routine clinical practice and evaluate molecular and cellular markers that may provide further prognostic classification and/or might be predictive of therapy outcomes.

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • E4512

    A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • LUNG-MAP

    Phase II/III Biomarker-Driven Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • NRG BR003

    A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • NSABP B51

    A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • S1418

    A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

    • Patients must have histologically confirmed ER-, PR- (can be <5%) and HER2-negative (TNBC) with residual invasive breast cancer after completion of neoadjuvant chemotherapy. Residual disease must be ≥ 1 cm in greatest dimension, and/or have positive lymph nodes (ypN+) observed on pathologic exam.
    • MK-3475 (pembrolizumab) IV every 3 weeks for 52 weeks vs. OBSERVATION
    • Registration involves: PD-L1 testing (must submit 5 unstained slides); sites are blinded to the results
    • NOTE: IHC-positive isolated tumor cells in the lymph node (N0 [i+]) are not considered node-positive and these patients also must have ≥ 1 cm residual invasive cancer in the breast in order to be eligible
    1. Patients can be ER and/or PR <5% - as long as MD states they are not eligible for adjuvant endocrine tx.
    2. Study is now compatible with EA1131 – re: sequencing with RT
    3. Capecitabine seen as a radiosensitizer – and does not have to be completed before RT can begin
       

    Principal Investigator: Anna Litvak, MD

    Website: https://clinicaltrials.gov/ct2/show/study/NCT02954874?term=S1418&rank=1&show_locs=Y#locn​

    For inquiries at Cooperman Barnabas Medical Center, call (973) 322-2470

    For inquiries at RWJ Somerset Medical Center, call (908) 685-2481

    • Cooperman Barnabas Medical Center
    • RWJ University Hospital Somerset
  • S1501

    Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase IIIbreast

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
Page of 2